Prostatype Genomics AB (PGO0)

Overview

Prostatype Genomics AB is a prominent biotechnology firm dedicated to the advancement and marketing of prognostic gene tests for prostate cancer. Founded in 2007 and headquartered in Solna, Sweden, the company has pioneered in developing a sophisticated Prostatype Test System designed to significantly enhance the decision-making process regarding treatment for prostate cancer patients. By integrating gene expression data with widely-used clinical parameters such as PSA levels, Gleason Score, and Tumor Stage, Prostatype Genomics AB delivers a comprehensive solution aimed at personalizing patient care.

Products and Services

The cornerstone of Prostatype Genomics AB's offering is the Prostatype Test System, which provides a pioneering approach to prostate cancer prognosis and treatment guidance. Below is a detailed look at their primary product:

• Prostatype Test System:

  This state-of-the-art system leverages gene expression information alongside established clinical parameters — specifically, PSA (Prostate-Specific Antigen) levels, Gleason Score, and Tumor Stage — to compute a P-score. The P-score is a unique metric that aids in assessing the aggressiveness of prostate cancer, which in turn, supports patients and healthcare providers in making informed decisions regarding the course of treatment. This innovative approach is supported by a comprehensive database containing information on prostate cancer patients, enhancing the accuracy and reliability of the test. Ultimately, the Prostatype Test System acts as a critical decision-support tool, aiming to tailor treatment options to individual patient profiles, thereby optimizing treatment outcomes.